Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
作者： Nirmala Chandralega Kampan , Mutsa Tatenda Madondo , Orla M. McNally , Michael Quinn , Magdalena Plebanski
DOI: 10.1155/2015/413076
关键词: Cisplatin 、 Taxane 、 Pharmacology 、 Standard care 、 Paclitaxel 、 Medicine 、 Cytotoxicity 、 Ovarian cancer 、 Oncology 、 Internal medicine 、 Dosing schedules
摘要: … for the treatment for ovarian cancer. To meet increasing demand… of paclitaxel as a treatment for advanced breast cancer. … the FDA approved paclitaxel for use against breast cancer. Pacli…
hindawi.com
core.ac.uk
researchgate.net 参考文章(161)
Seong H. Jang, M. Guillaume Wientjes, Jessie L.-S. Au, Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Investigational New Drugs. ,vol. 19, pp. 113- 123 ,(2001) , 10.1023/A:1010662413174
W. Freund, J. Lipke, T.-U. Hausamen, T. M. Löffler, Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. Seminars in Oncology. ,vol. 23, pp. 32- 34 ,(1996)
Sandro Pignata, Enrico Breda, Giovanni Scambia, Carmela Pisano, Vittorina Zagonel, Domenica Lorusso, Stefano Greggi, Rocco De Vivo, Gabriella Ferrandina, Ciro Gallo, Francesco Perrone, A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Critical Reviews in Oncology Hematology. ,vol. 66, pp. 229- 236 ,(2008) , 10.1016/J.CRITREVONC.2007.12.005
Partridge Ee, Clarke-Pearson Dl, Hoskins Wj, Brady Mf, Kucera Pr, Davidson M, Look Ky, McGuire Wp, Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Seminars in Oncology. ,vol. 23, pp. 40- 47 ,(1996)
C Aghajanian, D Spriggs, R R Barakat, D Fennelly, N R Abu-Rustum, F Shapiro, Salvage weekly paclitaxel in recurrent ovarian cancer. Seminars in Oncology. ,vol. 24, ,(1997)
Ronald E. Vale, Thomas Kreis, Guidebook to the cytoskeletal and motor proteins A Sambrook & Tooze Publication at Oxford University Press. ,(1993)
Ethan M. Shevach, CD4+CD25+ suppressor T cells: more questions than answers Nature Reviews Immunology. ,vol. 2, pp. 389- 400 ,(2002) , 10.1038/NRI821
Madhavi C. Chander, Susan Band Horwitz, Prabu Devanesan, Forrest H. Anthony, Sharyn D. Baker, Nigel L. Webb, Philip A. Witman, Lifeng He, Matthews O. Bradley, S. Hemamalini, Charles S. Swindell, Tumor Targeting by Covalent Conjugation of a Natural Fatty Acid to Paclitaxel Clinical Cancer Research. ,vol. 7, pp. 3229- 3238 ,(2001)
Y. Zhu, N. Liu, S. D. Xiong, Y. J. Zheng, Y. W. Chu, CD4+Foxp3+ regulatory T-cell impairment by paclitaxel is independent of toll-like receptor 4. Scandinavian Journal of Immunology. ,vol. 73, pp. 301- 308 ,(2011) , 10.1111/J.1365-3083.2011.02514.X
Alexander Y. Rudensky, Regulatory T cells and Foxp3 Immunological Reviews. ,vol. 241, pp. 260- 268 ,(2011) , 10.1111/J.1600-065X.2011.01018.X